Obesity and contraceptive use: impact on cardiovascular risk
Abstract Obesity and oestrogen containing contraceptive products are well‐known independent cardiovascular risk factors. However, a significant number of obese women continue to receive prescriptions of hormonal products that contain oestrogens for their contraception. We have conducted a narrative...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-12-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.14104 |
| _version_ | 1797979257413042176 |
|---|---|
| author | Giuseppe M.C. Rosano Maria Angeles Rodriguez‐Martinez Ilaria Spoletini Pedro Antonio Regidor |
| author_facet | Giuseppe M.C. Rosano Maria Angeles Rodriguez‐Martinez Ilaria Spoletini Pedro Antonio Regidor |
| author_sort | Giuseppe M.C. Rosano |
| collection | DOAJ |
| description | Abstract Obesity and oestrogen containing contraceptive products are well‐known independent cardiovascular risk factors. However, a significant number of obese women continue to receive prescriptions of hormonal products that contain oestrogens for their contraception. We have conducted a narrative review to discuss the latest evidence, ongoing research, and controversial issues on the synergistic effect of obesity and contraceptive use, in terms of cardiovascular risk. There is compelling evidence of an interplay between obesity and contraception in increasing cardiovascular risk. Women who present both obesity and use of combined oral contraceptives (COCs) have a greater risk (between 12 and 24 times) to develop venous thromboembolism than non‐obese non‐COC users. Data here discussed offer new insights to increase clinicians' awareness on the cardiovascular risk in the clinical management of obese women. The synergistic effect of obesity and COCs on deep venous thrombosis risk must be considered when prescribing hormonal contraception. Progestin‐only products are a safer alternative to COCs in patients with overweight or obesity. Obese women taking contraceptives should be viewed as an ‘at risk’ population, and as such, they should receive advice to change their lifestyle, avoiding other cardiovascular risk factors, as a form of primary prevention. This indication should be extended to young women, as data show that COCs should be avoided in obese women of any age. |
| first_indexed | 2024-04-11T05:36:04Z |
| format | Article |
| id | doaj.art-a229b857a0db4091941e230d5d871ab8 |
| institution | Directory Open Access Journal |
| issn | 2055-5822 |
| language | English |
| last_indexed | 2024-04-11T05:36:04Z |
| publishDate | 2022-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj.art-a229b857a0db4091941e230d5d871ab82022-12-22T12:55:33ZengWileyESC Heart Failure2055-58222022-12-01963761376710.1002/ehf2.14104Obesity and contraceptive use: impact on cardiovascular riskGiuseppe M.C. Rosano0Maria Angeles Rodriguez‐Martinez1Ilaria Spoletini2Pedro Antonio Regidor3Centre for Clinical and Basic Research, Department of Medical Sciences IRCCS San Raffaele Pisana Rome ItalyFreelance Consultant of Pharmacovigilance and Clinical Development Madrid SpainCentre for Clinical and Basic Research, Department of Medical Sciences IRCCS San Raffaele Pisana Rome ItalyExeltis Healthcare Ismaning GermanyAbstract Obesity and oestrogen containing contraceptive products are well‐known independent cardiovascular risk factors. However, a significant number of obese women continue to receive prescriptions of hormonal products that contain oestrogens for their contraception. We have conducted a narrative review to discuss the latest evidence, ongoing research, and controversial issues on the synergistic effect of obesity and contraceptive use, in terms of cardiovascular risk. There is compelling evidence of an interplay between obesity and contraception in increasing cardiovascular risk. Women who present both obesity and use of combined oral contraceptives (COCs) have a greater risk (between 12 and 24 times) to develop venous thromboembolism than non‐obese non‐COC users. Data here discussed offer new insights to increase clinicians' awareness on the cardiovascular risk in the clinical management of obese women. The synergistic effect of obesity and COCs on deep venous thrombosis risk must be considered when prescribing hormonal contraception. Progestin‐only products are a safer alternative to COCs in patients with overweight or obesity. Obese women taking contraceptives should be viewed as an ‘at risk’ population, and as such, they should receive advice to change their lifestyle, avoiding other cardiovascular risk factors, as a form of primary prevention. This indication should be extended to young women, as data show that COCs should be avoided in obese women of any age.https://doi.org/10.1002/ehf2.14104ObesityCombined oral contraceptivesVenous thromboembolismCardiovascular riskDeep venous thrombosis |
| spellingShingle | Giuseppe M.C. Rosano Maria Angeles Rodriguez‐Martinez Ilaria Spoletini Pedro Antonio Regidor Obesity and contraceptive use: impact on cardiovascular risk ESC Heart Failure Obesity Combined oral contraceptives Venous thromboembolism Cardiovascular risk Deep venous thrombosis |
| title | Obesity and contraceptive use: impact on cardiovascular risk |
| title_full | Obesity and contraceptive use: impact on cardiovascular risk |
| title_fullStr | Obesity and contraceptive use: impact on cardiovascular risk |
| title_full_unstemmed | Obesity and contraceptive use: impact on cardiovascular risk |
| title_short | Obesity and contraceptive use: impact on cardiovascular risk |
| title_sort | obesity and contraceptive use impact on cardiovascular risk |
| topic | Obesity Combined oral contraceptives Venous thromboembolism Cardiovascular risk Deep venous thrombosis |
| url | https://doi.org/10.1002/ehf2.14104 |
| work_keys_str_mv | AT giuseppemcrosano obesityandcontraceptiveuseimpactoncardiovascularrisk AT mariaangelesrodriguezmartinez obesityandcontraceptiveuseimpactoncardiovascularrisk AT ilariaspoletini obesityandcontraceptiveuseimpactoncardiovascularrisk AT pedroantonioregidor obesityandcontraceptiveuseimpactoncardiovascularrisk |